Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orthovita

This article was originally published in The Gray Sheet

Executive Summary

Malvern, Pennsylvania-based maker of bone substitute materials nets approximately $16.8 mil. from an initial public offering of 2.3 mil. shares of common stock at $10.50 per share on June 25. The offering, which included 1.5 mil. shares and a 300,000 share overallotment option offered by the company, as well as 500,000 shares offered by selling shareholders, was made through a retail public offering in Belgium. A secondary offering in the U.S. is anticipated when market conditions improve, the firm explains. The proceeds are tabbed for expansion of marketing and manufacturing activities, clinical trials of the company's bone cement and bone substitute products for various indications, and continued R&D. Orthovita, which has offered BioGran resorbable granular bone grafting material for dental surgical applications since 1995, plans to submit a 510(k) by the end of June for its Orthocomp bone bonding cement - initially for use in screw augmentation ("The Gray Sheet" Feb. 2, I&W-8). The company also is developing VitaGraft, a resorbable calcium phosphate bone substitute material. The IPO was managed by Quartz Capital Partners Limited, Artesia Bank and Bank Brussels Lambert...
UsernamePublicRestriction

Register

MT010275

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel